Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART-PSMA-TGF-beta RDN |
Synonyms | |
Therapy Description |
CART-PSMA-TGF-beta RDN is comprised of peripheral blood mononuclear cells engineered to express a dominant-negative TGFBRII lacking the kinase domain and a chimeric antigen receptor (CAR) that targets PSMA linked to the intracellular domains of 4-1BB and CD3zeta, which potentially induces killing of PSMA-expressing tumor cells and inhibits tumor growth (PMID: 29807781). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART-PSMA-TGF-beta RDN | Autologous PSMA-specific TGFb-resistant CAR T Cells | CART-PSMA-TGF-beta RDN is comprised of peripheral blood mononuclear cells engineered to express a dominant-negative TGFBRII lacking the kinase domain and a chimeric antigen receptor (CAR) that targets PSMA linked to the intracellular domains of 4-1BB and CD3zeta, which potentially induces killing of PSMA-expressing tumor cells and inhibits tumor growth (PMID: 29807781). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03089203 | Phase I | CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine | CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer | Active, not recruiting | USA | 0 |